Neurologix to Showcase Novel Brain and CNS Disease Gene Therapies at BioPharm America
FORT LEE, N.J.-(Business Wire)-September 14, 2009 - Neurologix, Inc. (OTCBB: NRGX), a biotechnology company engaged in the development of innovative gene therapies for the brain and central nervous system, announced today that the company will showcase its novel gene transfer approach to Parkinson’s disease and other serious brain and central nervous system diseases at the BioPharm America partnering conference being held in San Francisco, CA on September 17 – 18. John Mordock, Neurologix President and Chief Executive Officer, will discuss the company’s technology, ongoing Phase 2 trial in advanced Parkinson’s disease and other development programs from 4:15 – 4:30 on Thursday September 17 in Salon 14 at the Marriott San Francisco.
About Neurologix
Neurologix, Inc. (NRGX.OB) is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of life-altering gene transfer therapies for serious disorders of the brain and central nervous system (CNS). Neurologix’s therapeutic approach is built upon the groundbreaking research of its scientific founders and advisors, whose accomplishments have formed the foundation of gene therapy for neurological illnesses. Current programs of the company address such conditions as Parkinson’s disease, epilepsy and Huntington’s chorea, all of which are large markets not adequately served by current therapeutic options. For more information, please visit the Neurologix website at http://www.neurologix.net.
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
